background
although
viral
infect
major
caus
exacerb
patient
chronic
airway
diseas
role
trigger
bronchiectasi
exacerb
adult
remain
unclear
th
erefor
prospect
investig
incid
clinic
impact
viral
infect
adult
bronchiectasi
exacerb
th
e
studi
cohort
adult
bronchiectasi
follow
prospect
month
nasopharyng
swab
sputum
sampl
assay
respiratori
virus
use
polymeras
chain
reaction
assay
symptom
spirometri
qualiti
life
bacteri
cultur
infl
ammatori
marker
assess
steadyst
bronchiectasi
exacerb
total
exacerb
captur
patient
followup
respiratori
virus
found
frequent
nasopharyng
swab
sputum
bronchiectasi
exacerb
steadi
state
p
th
e
common
virus
found
patient
experienc
exacerb
coronaviru
rhinoviru
infl
uenza
ab
virus
virusposit
exacerb
associ
greater
increas
marker
system
airway
infl
ammat
serum
tumor
necrosi
factora
sputum
b
tumor
necrosi
factora
compar
virusneg
exacerb
diff
erenc
spirometr
index
qualiti
life
bacteri
densiti
unremark
receiv
oper
characterist
analysi
serum
interferong
induc
protein
yield
area
curv
ci
p
furthermor
greater
proport
patient
virusposit
exacerb
receiv
iv
antibiot
preval
viral
infect
detect
polymeras
chain
reaction
assay
higher
case
bronchiectasi
exacerb
steadyst
bronchiectasi
suggest
respiratori
virus
play
crucial
role
trigger
bronchiectasi
exacerb
potenti
mechan
virusinduc
bronchiectasi
exacerb
merit
investig
abbrevi
bronchiectasi
exacerb
bsi
bronchiectasi
sever
index
cat
copd
assess
test
cfu
colonyform
unit
crp
creactiv
protein
hcov
human
coronaviru
hrct
highresolut
ct
interferong
induc
protein
iqr
interquartil
rang
lcq
leicest
cough
questionnair
np
nasopharyng
swab
pcr
polymeras
chain
reaction
qol
qualiti
life
sgrq
st
georg
respiratori
questionnair
tnf
tumor
necrosi
factor
patient
bronchiectasi
frequent
develop
acut
infect
exacerb
character
increas
cough
frequenc
sputum
volum
purul
readili
lead
hospit
admiss
high
treatment
cost
importantli
frequent
exacerb
impos
advers
effect
qualiti
life
qol
might
acceler
loss
lung
function
increas
mortal
date
howev
trigger
bronchiectasi
exacerb
be
poorli
elucid
antibiot
treatment
be
shown
mitig
clinic
symptom
restor
lung
function
concurr
suppress
system
airway
inflammatori
respons
be
postul
result
airway
bacteri
infect
novel
strain
increas
bacteri
densiti
howev
tunney
et
al
show
total
bacteri
densiti
microbiota
taxa
analyz
cultur
ribosom
dna
pyrosequenc
chang
remark
antibiot
treatment
be
suggest
chang
lung
microbiota
composit
might
account
signifi
cantli
be
led
us
examin
role
poten
tial
pathogen
especi
virus
adult
bronchiectasi
well
establish
respiratori
viral
infect
major
trigger
acut
exacerb
copd
asthma
cystic
fi
brosi
recent
studi
children
bronchiectasi
found
respiratori
virus
detect
pediatr
pulmonologistdefi
ned
be
associ
wors
clinic
outcom
howev
signifi
canc
viral
infect
adult
be
remain
unknown
addit
clinic
characterist
investig
regard
virusassoci
be
adult
also
lack
interact
respiratori
virus
bacteria
host
immun
respons
might
directli
relat
pathogenesi
bronchiectasi
shown
copd
deserv
special
attent
research
clinician
meanwhil
biomark
serum
interferong
induc
protein
propos
surrog
marker
predict
virusassoci
exacerb
copd
util
bronchiectasi
never
assess
prospect
studi
sought
document
incid
common
respiratori
virus
adult
bronchiectasi
steadyst
bronchiectasi
be
investig
clinic
diff
erenc
virusposit
virusneg
be
assess
util
serum
predict
virusrel
be
patient
bronchiectasi
diagnos
compat
histori
combin
bronchial
dilat
highresolut
ct
hrct
scan
recruit
outpati
clinic
th
e
first
affi
liat
hospit
guangzhou
medic
univers
previou
cohort
assess
eff
ect
anxieti
depress
be
within
span
month
patient
assess
baselin
clinic
stabl
be
followup
patient
requir
attend
chest
clinic
routin
everi
month
neighbor
schedul
visit
patient
experienc
symptom
exacerb
request
contact
investig
immedi
addit
visit
schedul
within
h
be
defi
ned
persist
h
deterior
least
three
respiratori
symptom
includ
cough
dyspnea
hemoptysi
increas
sputum
purul
volum
chest
pain
febril
radiograph
deterior
system
disturb
chang
chest
auscult
spontan
induc
sputum
collect
visit
bacteri
cultur
viral
assay
measur
airway
infl
ammat
pair
serum
sampl
collect
assess
system
infl
ammat
paramet
measur
clinic
stabl
time
comprehens
histori
includ
age
sex
bmi
infl
uenza
vaccin
preced
year
number
infect
exacerb
hospit
previou
month
current
treatment
record
baselin
chest
hrct
scan
within
month
use
radiolog
score
base
number
bronchiectat
lobe
lingula
score
separ
lobe
sever
bronchial
dilat
tubular
point
varicos
point
cystic
point
maxim
score
etiolog
bronchiectasi
determin
meticul
test
recommend
british
thorac
societi
guidelin
group
discuss
yonghua
gao
w
g
g
x
upper
lower
airway
symptom
record
clinic
stabl
be
bronchiectasi
sever
baselin
quantifi
ed
accord
bronchiectasi
sever
index
bsi
qol
assess
use
st
georg
respiratori
questionnair
sgrq
leicest
cough
questionnair
lcq
copd
assess
test
cat
patient
clinic
stabl
fi
rst
be
one
exacerb
method
assess
sputum
bacteri
densiti
pseudomona
aeruginosa
haemophilu
infl
uenza
potenti
pathogen
microorgan
introduc
previous
detail
provid
eappendix
detail
lung
function
measur
given
eappendix
level
b
tumor
necrosi
factor
tnf
sputum
tnfa
serum
measur
use
commerci
multiplex
beadbas
assay
kit
bioplex
cytokin
assay
biorad
inc
creactiv
protein
crp
level
wbc
count
also
measur
system
inflammatori
marker
detail
given
eappendix
nasopharyng
swab
np
sputum
sampl
virolog
analysi
sixteen
common
respiratori
tract
pathogen
test
use
taqman
revers
transcriptasepolymeras
chain
reaction
pcr
previous
report
includ
rhinoviru
infl
uenza
virus
b
parainfl
uenza
virus
human
coronoviru
hcov
respiratori
syncyti
viru
adenoviru
enteroviru
bocaviru
human
metapneumoviru
specimen
cycl
threshold
deem
posit
accord
manufactur
specif
guangzhou
huyansuo
medic
technolog
co
ltd
lower
cycl
threshold
valu
indic
fewer
cycl
pcr
amplifi
cation
need
detect
viral
nucleic
acid
henc
refl
ect
higher
magnitud
pcr
posit
detail
viru
detect
provid
eappendix
studi
investig
role
viral
infect
bronchiectasi
lack
assum
detect
rate
virus
np
sputum
steadyst
bronchiectasi
imput
copd
particip
baselin
subgroup
exacerb
subgroup
followup
requir
detect
diff
erenc
proport
viral
infect
twosid
signifi
canc
level
p
power
therefor
plan
includ
patient
assum
dropout
rate
captur
suffi
cient
exacerb
event
follow
data
present
mean
sd
median
interquartil
rang
iqr
count
proport
appropri
bacteri
densiti
colonyform
unit
cfu
ml
logarithm
transform
analys
categor
variabl
compar
use
x
test
continu
variabl
twogroup
comparison
perform
use
unpair
test
mannwhitney
test
appropri
oneway
analysi
varianc
kruskalw
test
appli
multiplegroup
comparison
appropri
logist
regress
analys
perform
examin
relationship
independ
variabl
presenc
virus
th
e
util
predict
viral
infect
be
investig
use
receiv
oper
characterist
curv
result
present
area
curv
ci
p
valu
consid
statist
signifi
cant
analys
statist
analys
perform
use
spss
ibm
graphpad
prism
version
graphpad
soft
ware
inc
patient
recruit
fig
least
one
report
followup
includ
final
analys
patient
experienc
be
report
be
followup
studi
period
patient
report
be
experienc
be
fail
report
therefor
sampl
th
ese
patient
total
unreport
exacerb
th
us
patient
total
exacerb
mean
exacerb
per
patient
per
year
whole
studi
period
th
e
characterist
underli
caus
bronchiectasi
includ
patient
diff
er
patient
drop
tabl
e
tabl
patient
pseudomona
aeruginosa
colon
baselin
one
receiv
infl
uenza
vaccin
autumn
studi
patient
idiopathicpostinfect
bronchiectasi
baselin
cohort
baselin
characterist
use
diff
erent
bsi
score
present
onlin
supplement
e
tabl
median
time
sampl
iqr
unrel
viru
detect
p
respiratori
virus
detect
np
sputum
report
be
patient
bronchiectasi
baselin
experienc
exacerb
p
fig
none
adult
virusposit
baselin
ident
viru
detect
subsequ
exacerb
th
irti
posit
respiratori
viru
first
be
patient
two
report
be
four
ident
viru
two
differ
be
event
virus
detect
includ
episod
multipl
virus
e
tabl
th
ree
patient
report
exacerb
multipl
virus
isol
steadyst
bronchiectasi
one
infl
uenza
rhinoviru
infl
uenza
infl
uenza
th
e
distribut
virus
detect
shown
tabl
accord
studi
group
type
specimen
analyz
th
e
common
virus
coronaviru
rhinoviru
infl
uenza
b
th
e
detect
virus
be
accord
bronchiectasi
sever
assess
bsi
summar
e
tabl
patient
moder
sever
bronchiectasi
bsi
higher
posit
viral
infect
mild
bronchiectasi
bsi
vs
respect
p
complet
set
virolog
sampl
np
sputum
collect
episod
without
miss
sampl
virus
could
detect
compar
fi
virus
fi
patient
th
e
odd
virusposit
be
associ
individu
symptom
summar
e
tabl
block
nose
hoars
common
virusposit
be
qol
measur
patient
fi
rst
be
virusposit
group
virusneg
group
chang
sgrq
lcq
cat
total
score
be
steadyst
bronchiectasi
patient
virusposit
group
signifi
cant
albeit
statist
signifi
cant
patient
virusneg
group
tabl
fig
th
e
posit
neg
predict
valu
respect
knowledg
fi
rst
largescal
prospect
studi
determin
incid
clinic
impact
viral
infect
use
pcrbase
method
be
adult
found
follow
be
signifi
cantli
associ
presenc
virus
np
sputum
coronaviru
rhinoviru
infl
uenza
viru
common
virusposit
be
associ
signifi
cant
increas
system
airway
infl
ammatori
marker
prone
requir
iv
antibiot
therapi
compar
virusneg
be
viral
infect
be
signifi
cant
eff
ect
qol
albeit
greater
deterior
virusposit
be
lung
function
bacteri
densiti
serum
level
limit
signifi
canc
predict
viral
infect
be
detect
respiratori
virus
signifi
cantli
oft
en
be
steadyst
bronchiectasi
th
e
overal
incid
viral
infect
be
consist
previou
studi
regard
pediatr
bronchiectasi
copd
cystic
fi
brosi
th
erefor
rate
viral
carriag
stabl
chronic
airway
diseas
includ
bronchiectasi
might
signifi
cantli
diff
erent
healthi
adult
popul
intrigu
fi
nding
detect
rate
respiratori
virus
be
higher
moder
sever
bronchiectasi
ie
bsi
eappendix
th
e
underli
interpret
remain
entir
unclear
could
follow
particip
moder
sever
bronchiectasi
prone
virusinduc
be
due
impair
innat
interferon
product
follow
viral
infect
evidenc
patient
asthma
particip
moder
sever
bronchiectasi
like
harbor
bacteri
colon
might
increas
suscept
viru
upregul
intercellular
cell
adhes
rel
small
number
be
might
bias
estim
underli
relationship
viral
infect
bronchiectasi
sever
shown
viral
infect
be
impact
signifi
cantli
qol
might
explain
fact
system
lower
airway
symptom
signifi
cantli
diff
erent
virusposit
virusneg
be
discrimin
abil
aforement
unspecifi
c
questionnair
limit
addit
viral
infect
be
associ
mark
chang
fev
baselin
impli
fev
sensit
marker
be
diseasespecifi
c
questionnair
sensit
indic
spirometri
lung
clearanc
index
merit
investig
determin
whether
viral
infect
be
associ
wors
qol
greater
reduct
lung
function
serum
promis
indic
virusassoci
exacerb
copd
although
serum
increas
virusposit
be
found
diagnost
accuraci
poor
predict
viral
infect
be
given
low
posit
neg
predict
valu
fi
nding
suggest
serum
ideal
surrog
laboratoryconfi
rmed
viral
infect
be
clinic
practic
research
novel
biomark
identifi
virusassoci
be
urgent
need
guid
futur
antivir
therapi
antivir
agent
becom
increasingli
avail
th
e
potenti
clinic
implic
studi
follow
determin
contribut
variou
respiratori
viru
type
be
would
er
rational
antivir
therapi
supplement
virolog
data
would
better
guid
appropri
antibiot
use
clinic
futur
provis
evid
infl
uenza
vaccin
popul
high
risk
bronchiectasi
inspir
futur
investig
regard
mechan
virusinduc
exacerb
especi
defi
cient
interferon
product
bronchiectasi
extens
understand
pathophysiolog
mechan
relev
bronchiectasi
reli
extrapol
evid
cystic
fi
brosi
th
studi
inher
limit
patient
request
contact
investig
be
occur
therefor
milder
be
mirror
upper
respiratori
tract
infect
might
underreport
th
e
schedul
followup
investig
determin
eff
ect
viral
infect
symptom
recoveri
could
perform
poor
complianc
lack
valid
electron
diari
card
th
refl
ect
reallif
practic
patient
frequent
unwil
record
symptom
use
daili
paper
diari
china
set
singl
medic
center
fi
nding
need
valid
multicent
studi
summari
shown
respiratori
virus
major
trigger
be
adult
studi
determin
mechan
virusinduc
be
virus
impact
lowerairway
microbi
commun
merit
